Adventrx Pharmac. Heisses Eisen ?

News??? Oder wird heute wieder mal gezockt. Gruß  

ADVENTRX Receives Brand Name Acceptance for ANX-530
Buzz up! 0
Print
Companies:Adventrx Pharmaceuticals, Inc.
Related Quotes
Symbol Price Change
ANX 0.21 0.00

Press Release Source: ADVENTRX Pharmaceuticals, Inc. On Friday March 12, 2010, 8:00 am
SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the U.S. Food and Drug Administration (FDA) has accepted the proposed proprietary name "Exelbine™" for the Company's product candidate ANX-530 (vinorelbine injectable emulsion).

"We are pleased with the FDA's response to our proprietary name request and look forward to continued regulatory progress on ANX-530," said Brian M. Culley, Chief Executive Officer of ADVENTRX.

Following completion of its review process, the FDA concluded that "Exelbine" is acceptable provided the information presented by ADVENTRX regarding the safety of interchanging ANX-530 with other vinorelbine injectable products is confirmed during review of an ANX-530 New Drug Application (NDA).

As previously announced, the Company submitted an NDA for ANX-530 to the FDA in December 2009. In March 2010, the Company announced that it had received a refusal-to-file letter from the FDA regarding its ANX-530 NDA submission. In the letter, the FDA indicated that the data included in the December 2009 NDA submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. The FDA identified only this one chemistry, manufacturing and controls (CMC) reason for the refusal to file. ADVENTRX has requested a face-to-face meeting with the FDA to understand its requirements and define the path to a successful filing of an ANX-530 NDA at the earliest possible time.

http://finance.yahoo.com/news/ADVENTRX-Receives-Brand-Name-p…  

ADVENTRX Sets Meeting With FDA to Discuss ANX-530 NDA

SAN DIEGO, March 26 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it will meet the U.S. Food and Drug Administration (FDA) in Washington D.C. during the last week of April 2010 to review the Company's New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion) and the FDA's refusal-to-file letter.



ADVENTRX had requested a face-to-face meeting with the FDA to understand its requirements and define the path to a successful filing of an ANX-530 NDA at the earliest possible time.


"We look forward to meeting with the agency next month to clarify the necessary steps for filing the ANX-530 NDA this year," said Brian M. Culley, Chief Executive Officer of ADVENTRX.


ADVENTRX submitted an NDA for ANX-530 to the FDA in December 2009. The Company announced on March 1, 2010 that it had received a refusal-to-file letter from the FDA regarding that submission. In the letter, the FDA indicated that the data included in the December 2009 NDA submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. The FDA identified only this one chemistry, manufacturing and controls (CMC) reason for the refusal to file. No clinical or nonclinical issues were identified.

http://pharmalive.com/News/Index.cfm?articleid=694004  

Adventrx Pharmaceuticals Inc., of San Diego, will meet with the FDA during the last week of April to discuss its new drug application for ANX-530 (vinorelbine injectable emulsion), which received a refuse-to-file letter earlier this month due to manufacturing deficiencies. ANX-530 is an emulsion of the chemotherapy drug vinorelbine, and Adventrx is seeking approval for non-small-cell lung cancer. (See BioWorld Today, March 2, 2010.)

Hat das was zu sagen, wenn laufend 100 oder 200 Stücke über den Tisch gehen?
Das lohnt sich doch im Grunde gar nicht für den Einzelnen. Komisch???

Zeit Kurs + Zusatz Umsatz Umsatz kumuliert
  21:03:35§ 0,218 400 2.013.987
  21:02:56§ 0,218 500 2.013.587
  21:02:56§ 0,218 200 2.013.087
  21:01:53§ 0,218 100 2.012.887
  21:01:09§ 0,218 200 2.012.787
  21:00:52§ 0,218 100 2.012.587
  20:59:32§ 0,218 100 2.012.487
  20:59:13§ 0,218 100 2.012.387
  20:58:10§ 0,218 200 2.012.287
  20:58:06§ 0,218 10.000 2.012.087
  20:56:57§ 0,218 100 2.002.087
  20:56:54§ 0,218 100 2.001.987
  20:56:54§ 0,218 100 2.001.887
  20:56:50§ 0,218 100 2.001.787
  20:56:47§ 0,218 100 2.001.687
  20:56:43§ 0,218 100 2.001.587
  20:56:39§ 0,218 100 2.001.487
  20:56:36§ 0,218 100 2.001.387
  20:56:32§ 0,218 100 2.001.287
  20:56:29§ 0,218 100 2.001.187
  20:56:25§ 0,218 100 2.001.087
  20:56:23§ 0,218 12.000 2.000.987
  20:56:21§ 0,218 100 1.988.987
  20:56:18§ 0,218 100 1.988.887
  20:56:14§ 0,218 100 1.988.787
  20:56:11§ 0,218 100 1.988.687
  20:56:07§ 0,218 100 1.988.587
  20:56:04§ 0,218 100 1.988.487
  20:56:00§ 0,218 100 1.988.387
  20:55:56§ 0,218 100 1.988.287
  20:55:54§ 0,218 100 1.988.187
  20:55:53§ 0,218 100 1.988.087
  20:55:49§ 0,218 100 1.987.987
  20:55:46§ 0,218 100 1.987.887
  20:55:42§ 0,218 100 1.987.787
  20:55:39§ 0,218 100 1.987.687
  20:55:35§ 0,218 100 1.987.587
  20:55:31§ 0,218 100 1.987.487
  20:55:28§ 0,218 100 1.987.387
  20:55:24§ 0,218 100 1.987.287
  20:55:21§ 0,218 100 1.987.187
  20:55:17§ 0,218 100 1.987.087
  20:55:13§ 0,218 100 1.986.987
  20:55:10§ 0,218 100 1.986.887
  20:55:06§ 0,218 100 1.986.787
  20:55:03§ 0,218 100 1.986.687
  20:54:59§ 0,218 100 1.986.587
  20:54:56§ 0,218 100 1.986.487
  20:54:53§ 0,218 100 1.986.387
  20:54:52§ 0,218 100 1.986.287
  20:54:52§ 0,218 100 1.986.187
  20:54:48§ 0,218 100 1.986.087
  20:54:45§ 0,218 100 1.985.987
  20:54:41§ 0,218 100 1.985.887
  20:54:38§ 0,218 100 1.985.787
  20:54:35§ 0,218 5.000 1.985.687
  20:54:34§ 0,218 100 1.980.687
  20:54:30§ 0,218 100 1.980.587
  20:54:27§ 0,218 100 1.980.487
  20:54:23§ 0,218 100 1.980.387
  20:54:20§ 0,218 100 1.980.287
  20:54:16§ 0,218 100 1.980.187
  20:54:12§ 0,218 100 1.980.087
  20:54:09§ 0,218 100 1.979.987
  20:54:05§ 0,218 100 1.979.887
  20:54:02§ 0,218 100 1.979.787
  20:53:58§ 0,218 100 1.979.687
  20:53:54§ 0,218 100 1.979.587
  20:53:51§ 0,218 100 1.979.487
  20:53:50§ 0,218 200 1.979.387
  20:53:47§ 0,218 100 1.979.187
  20:53:44§ 0,218 100 1.979.087
  20:53:40§ 0,218 100 1.978.987
  20:53:40§ 0,218 100 1.978.887
  20:53:40§ 0,218 100 1.978.787
  20:53:36§ 0,218 100 1.978.687
  20:53:33§ 0,218 100 1.978.587
  20:53:29§ 0,218 100 1.978.487
  20:53:26§ 0,218 100 1.978.387
  20:53:22§ 0,218 100 1.978.287
  20:53:18§ 0,218 100 1.978.187
  20:53:18§ 0,218 100 1.978.087
  20:53:18§ 0,218 100 1.977.987
  20:53:15§ 0,218 100 1.977.887
  20:53:11§ 0,218 100 1.977.787
  20:53:08§ 0,218 100 1.977.687
  20:53:04§ 0,218 100 1.977.587
  20:53:01§ 0,218 100 1.977.487
  20:52:59§ 0,218 300 1.977.387
  20:52:33§ 0,218 200 1.977.087
  20:52:16§ 0,218 200 1.976.887
  20:52:16§ 0,218 100 1.976.687
  20:52:05§ 0,218 500 1.976.587
  20:51:55§ 0,218 300 1.976.087
  20:51:45§ 0,218 500 1.975.787
  20:51:45§ 0,218 1.000 1.975.287
  20:51:36§ 0,218 900 1.974.287
  20:51:33§ 0,218 200 1.973.387
  20:51:26§ 0,218 1.000 1.973.187
  20:51:17§ 0,218 100 1.972.187
Seite 3 / 22   1 2 3 4 5 6 7 8      

Ja ist mir die letzten Handelstage auch aufgefallen.Kann sein das sich mit kleinen Pos. unten eingedeckt wird.Ist mir schon bei vielen Aktien aufgefallen.Die meisten sind danach stark gestiegen!Also lassen wir uns mal positiv überraschen.Indem sinne wünsch euch ein Frohes Osterfest.Gruß  

Sorry habe wahrscheinlich ein Problem mit meinen Schreibprogramm  

Ist da was dran, das Carl Icahn hier investiert ist?
ca. 3,5 Millionen Aktien.
Was in meinen Augen nur ein Tropfen auf den heißen Stein ist.
Bei zur Zeit insgesamt 257 Millionen Aktien.

http://www.gurufocus.com/holdings.php?GuruName=Carl+Icahn

Geht heut schön Richtung Norden

 

Na ja, etwas besser als das Sparbuch. ;-)

Kann mir nicht helfen, der Kurs wird doch ständig manipuliert.
Diese Aktienpakete zu 100 und 200 Stück, das ist doch nicht normal.

Jetzt findet wohl das große fressen statt.

http://de.mimi.hu/borse/iceberg_order.html

Gehts heute mal wieder Richtung Norden???  

So wie es aussieht haben die Amis die 0,30 fest in Auge!  

Schauen wir mal ob das was wird...Zeit wird es ja mal langsam wieder...  

ADVENTRX Resolves NYSE Amex Listing Deficiencies


Plans Reverse Stock Split to Address Exchange's Low Stock Price Concern


SAN DIEGO, April 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it has resolved the stockholders' equity continued listing deficiencies originally identified by the NYSE Amex in a June 2009 letter to the Company. In part to address the NYSE Amex's requirement that the Company address its low stock price, ADVENTRX also announced that its Board of Directors has approved a 1-for-25 reverse split of its common stock, which was authorized by its stockholders at a special meeting held in August 2009. The Company's common stock will begin trading on a split adjusted basis on the NYSE Amex when the market opens on Monday, April 26, 2010.

In June 2009, the NYSE Amex notified the Company that it was not in compliance with the NYSE Amex's continued listing standards related to stockholders' equity. Through financing activity in 2009, ADVENTRX increased its stockholder's equity to approximately $6.7 million as of December 31, 2009, which exceeds continued listing standards related to stockholders' equity. In April 2010, the NYSE Amex notified the Company that, based on a review of publicly available information, ADVENTRX has resolved the continued listing deficiencies originally identified in the June 2009 letter. According to the April 2010 letter, the Company must demonstrate compliance with the continued listing standards for two consecutive quarters and/or by December 1, 2010, otherwise the NYSE Amex may initiate delisting procedures. In part as a result of a financing completed in January 2010, the Company anticipates complying with continued listing standards related to stockholders' equity at March 31, 2010.

The reverse stock split is intended to satisfy the NYSE Amex's determination in the June 2009 letter that it is appropriate for the Company to effect a reverse stock split to address its low price per share and that, if a reverse stock split is not completed within a reasonable amount of time, the NYSE Amex may initiate delisting procedures. The Company also believes that a higher share price could broaden ADVENTRX's appeal to investors, in addition to reducing per share transaction fees and certain administrative costs.

The reverse split will be effective upon the close of trading on Friday, April 23, 2010, and the Company's common stock will begin trading on a split adjusted basis on the NYSE Amex when the market opens on Monday, April 26, 2010. The reverse split will reduce the number of shares of the Company's common stock outstanding from approximately 257 million to approximately 10.3 million. Proportional adjustments will be made to ADVENTRX's outstanding stock options, warrants and other equity awards and to its equity compensation plans. Par value and the number of authorized shares of common stock will not change. The Company will not issue any fractional shares. Stockholders will receive cash in lieu of fractional shares to which they would otherwise be entitled.

Information for Stockholders regarding Reverse Stock Split

Registered holders of ADVENTRX common stock will receive a letter of transmittal shortly after the effective date of the reverse stock split with instructions for the exchange of their old stock certificates or the electronic adjustment of their holdings through the direct registration system, as applicable. American Stock Transfer and Trust Company will act as the exchange agent and can be contacted at (877) 2486417. Stockholders with shares in brokerage accounts will be contacted by their brokers with instructions.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will not meet the NYSE Amex's stockholders' equity continued listing standards for two consecutive quarters and/or by December 1, 2010 and that the NYSE Amex staff will commence delisting proceedings; the risk of negative market reaction following announcement and/or implementation of the planned reverse stock split, resulting in stock price decline; the risk of unexpected delays in completing the reverse stock split; the risk that NYSE Amex will commence delisting proceedings based on a future low selling price per share; the risk that ADVENTRX will pursue development activities at levels or on timelines, or will incur unexpected expenses, that shortens the period through which it is able to comply with NYSE Amex continued listing requirements related to stockholders' equity; the risk that ADVENTRX will be unable to raise sufficient additional capital to continue to develop, seek regulatory approval of and commercialize its product candidates while maintaining compliance with NYSE Amex continued listing requirements related to stockholders' equity; the risk of difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ADVENTRX's lead product candidates; ADVENTRX's reliance on the performance of third parties to assist in the conduct of its bioequivalence trials, regulatory submissions, CMC activities and other important aspects of its product candidate development programs, and that such third parties may fail to perform as expected; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2009. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov/.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement as set forth in this press release to reflect events or circumstances arising after the date on which it was made.  

Toll, und vorher wurde erst einmal eine Kapitalerhöhung durchgeführt.
Da stehen einen ja die Nackenhaare zu Berge.  

Bin zum Glück hier nur mit noch kleinen Posi. drin.Wenns weiter runter geht leg ich noch mal nach. Gruß  

Das werde ich bestimmt nicht tun.
Bei einen R/S sind die Kurse immer danach stark gefallen.
Hier geht nur noch eins, raus!!!

naja...Bei Genta ist nach dem ReSplit der Kurs gestiegen....
Aber das hier ist echter Murx....  

Ich hab zwar keine Ahnung was jetzt die Tage passiert, Allerdings sind meine Aktien momentan aktuell Stand 26.4.2010 13.10Uhr gesperrt und können nicht verkauft werden.

Hat jmd eine Ahnung was hier weiter vor sich geht ?

 

Hängt mit dem Resplit zusammen der Heute ist. Gruß